A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
Items 401–500 of 576
Wang, T., Gao, C., Li, J., Li, L., Yue, Y., Liu, X., Chen, S., Hou, Z., Yin, Y., Jiang, W., et al. (2023) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231210787 · Cited by 3
Li, Y., Zhou, J., Zheng, W., He, X., Liang, L., & Sunzi, K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1331780 · Cited by 3
“Beyond the personal distress experienced by individuals with severe depression, there is a considerable socioeconomic burden associated with this mental illness, resulting in collective costs ranging from US$29 to US$48 billion in the United States alone (8).”
BackgroundKim, E., Jeong, A., Lee, D. H., Park, D., & Jeon, J. Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.028 · Cited by 4
Emotional Development and Depression
Palmer, A. R., Lakhan-Pal, S., & Cicchetti, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-17332-6_26 · Cited by 11
Clarke, J. C. (2020) · Psychoanalytic Psychotherapy · doi:10.1080/02668734.2021.1877187 · Cited by 3
Kikkert-Hurkens, I. A. K., Spijker, J., van Bennekom, M. L., & Vrijsen, J. N. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114275 · Cited by 3
Neural mechanisms underlying susceptibility factors in depression
Jie, M. E. N. G., Wang, K., Peng, X. I. E., Wang, T., & Qiu, J. (2016) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972015-00579 · Cited by 3
Complementary and Alternative Therapies for Treatment-Resistant Depression: A Clinical Perspective
Yoon, R. S. Y., Ravindran, N., & Ravindran, A. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-70311-4_12 · Cited by 5
Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis
Griffiths, C., O’Neill-Kerr, A., Vai, R. D., Sore, T., & da Silva, K. M. (2019) · Open Journal of Depression · doi:10.4236/ojd.2019.83007 · Cited by 4
“Around 75% of the total costs related to depression are attributable to treatment resistant depression (TRD) (Mrazek et al., 2014).”
BackgroundThe Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.
Daniel, D. G., Daniel, N. G., Daniel, D. T., Flynn, L. C., & Allen, M. H. (2019) · PubMed Central · Cited by 4
Application of the Delphi Method in the Study of Depressive Disorder
Wu, H., Xu, L., Zheng, Y., Shi, L., Zhai, L., & Xu, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.925610 · Cited by 4
Systematic review of structured care pathways in major depressive disorder and bipolar disorder
Kim, H. K., Banik, S., Husain, M. I., Tang, V. M., Levitan, R. D., Daskalakis, Z. J., & Kloiber, S. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04379-z · Cited by 10
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Armas-Salazar, A., Fernandez-Gutiérrez, L. M., Jader, A., Avecillas-Chasin, J. M., Aronson, J. P., Pacheco-Barrios, N. V., & Altamirano, J. M. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108703 · Cited by 4
Yan, Z., Chang, L., Sun, S., & Sun, Z. (2025) · Neuroreport · doi:10.1097/wnr.0000000000002213 · Cited by 2
Chen, L., Chang, W.-C., Chung, C.-H., Sack, A. T., Lin, C., & Chang, H.-A. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116926 · Cited by 2
Wilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
The Effectiveness of Art Therapy on Adults With Depression: A Systematic Review and Meta‐Analysis
Qiao, L., Zhu, B., Liu, P., & Chen, X. (2026) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.70127 · Cited by 3
Boskovic, D. H., Huang, D., Severtson, S. G., Marci, C. D., Awasthi, S., Ardic, F. C., Eisenberg, D. F., & Kapadia, S. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01027-6 · Cited by 2
Advances in research on the pathogenesis of depression based on signaling pathways
Chen, L. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202021803017 · Cited by 2
Neuroimaging Studies of Effects of Psychotherapy in Depression
Bauer, I. E., & Meyer, T. D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.021 · Cited by 2
Depression roundtable: Is there a role for BoNT?
Kels, L. H. (2023) · Toxicon · doi:10.1016/j.toxicon.2023.107148 · Cited by 3
Phillips, J. L., Blier, P., & Talbot, J. D. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100613 · Cited by 6
Recco, K. C. C., Bonetto, G. G., Lupo, C., Nardi, A. E., Morales, A., Becerra‐Palars, C., Perocco, S., & Pfau, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1221746 · Cited by 2
“…patients have more severe clinical presentation than other MDD patients, are more prone to suicidality, have a higher proportion of comorbidities, have higher healthcare resource utilization, resulting in higher economic burden of the disease, and negative outcomes on quality of life (4, 31, 32).”
BackgroundInfluentialTreatment-Resistant Depression in Colombia: Results From a Longitudinal Analysis of the TRAL Study
Baena, L. M. A., Cordoba-Rojas, R., Ferro, E., KANEVSKY, G. A., & Perocco, S. (2023) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2023.11.006 · Cited by 2
Trend and geo-availability of somatic therapies for treatment resistant depression in the US
Basiru, T., Onyeaka, H., Oladunjoye, A. F., Acholonu, C., Egbeocha, S., Ogala, F., Enemuo, S., Okoronkwo, O. U., Annor, E., Holmes, K., et al. (2024) · Psychiatry Research Communications · doi:10.1016/j.psycom.2024.100157 · Cited by 4
Relating depressive and manic symptomatology to 1H-MRS spectra
Choquette, A., Dager, A. D., Marjańska, M., Zatony, M., Pearlson, G. D., Glahn, D. C., & Knowles, E. E. M. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100774 · Cited by 3
Screening of Novel Hydroxamic Acid Derivatives as ASM Inhibitors for the Treatment of Depression
Gupta, S., Asati, V., Ali, A., Chtita, S., Kaya, S., & Ali, A. (2024) · ChemistrySelect · doi:10.1002/slct.202403803 · Cited by 2
Calabrò, M., Fabbri, C., Serretti, A., Kasper, S. F., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., et al. (2025) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000379 · Cited by 4
“Ineffective treatments are not only a waste of time and resources, but they are likely to adversely influence the patient’s confidence in the healthcare system (Mrazek et al ., 2014; Christensen et al ., 2020).”
Xiao, J., Dong, X., Ding, M., Yang, Q., & Kong, T. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1518255 · Cited by 3
“In addition, depression causes an annual economic burden of approximately $118 billion (14) and a considerable financial burden on health care (15).”
The economic burden of treatment-resistant depression: Cost-of-illness perspective
Niazi, S. K., & Bobo, W. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00003-7 · Cited by 3
Holborn, T., Schifano, F., Smith, E., & Deluca, P. (2025) · Psychoactives · doi:10.3390/psychoactives4030028 · Cited by 4
Wang, S., Anderson, I. M., Mitchell, D., Johnson, S. J., & Shiozawa, A. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s181718 · Cited by 4
“TRD is associated with considerable patient and economic burden.(7,8) In the United Kingdom, in 2009/2010, 12% of all depressed patients were considered to have TRD, presenting an annual total cost of £3.”
BackgroundEpidemiology and Burden of Treatment-Resistant Depression in Colombia: Analysis of the TRAL Study
Cordoba-Rojas, R., Ferro, E., Baena, L. M. A., KANEVSKY, G. A., & Cabrera, P. (2023) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2023.04.009 · Cited by 3
Prevalence of Treatment Resistant Depression: TRAL study sub analysis in a Mexican sample
Hernández, J. L. V., de la Serna, L. D. A., de la Cruz, C. D. L. C. C., Palars, C. B., Beltran, J. I., KANEVSKY, G. A., & Cabrera, P. (2023) · Archivos de Neurociencias · doi:10.31157/an.v28i4.448 · Cited by 2
“In a context of limited healthcare resources, the significant economic burden 11 and the influence of MDD/TRD on Quality of Life (QoL), disability, and work-productivity 5,12,13 are major concerns.”
BackgroundInfluentialKogut, S. J., Quilliam, B. J., Marcoux, R. M., McQuade, W., Wojciechowski, C., Wentworth, C. E., Plonsky, R., & Wood, N. (2016) · PubMed · Cited by 2
Combination Strategies in Treatment-Resistant Depression
Lopez-Munoz, F. J., Álamo, C., & García‐García, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_28 · Cited by 3
Wang, M., Xiong, Z., Su, B., Wang, L., Li, Z., Yang, Y., Fang, J., & Li, Z. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13041 · Cited by 5
“We excluded bipolar disorder according to her score (4) on the Mood Disorder Questionnaire.”
MethodPsychiatrische Polypharmazie und Elektrokonvulsionstherapie bei therapieresistenter Depression
Zöllner, R., Huber, M., Mangelsdorf, C., Konrad, C., & Zavorotnyy, M. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-00804-z · Cited by 2
Electrophysiological Biomarkers for Mood Disorders
Ramakrishnan, N., Murphy, N., Selvaraj, S., & Cho, R. Y. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.015 · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Andrade-Silva, J., May, G., Gueuvoghlanian-Lopes, B., de Freitas, I. C. M., Souza, B. L. S., May, P., & Teich, V. (2024) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v15.n3.p178-189 · Cited by 3
Roystonn, K., Koh, Y. S., Shafie, S., Sambasivam, R., Vaingankar, J. A., Chong, S. A., & Subramaniam, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.046 · Cited by 2
Ghitza, U. E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1624642 · Cited by 1
Clemens, K., Rive, B., Joshi, K., Thilakarathne, P. J., Kirson, N. Y., Desai, U. S., Doran, J., Eid, D., Qu, A., & Godinov, Y. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2555483 · Cited by 1
“These individuals with TRD have been associated with high health care, economic and societal burden 8–10 .”
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Rodríguez‐Landa, J. F., Puig-Lagunes, Á. A., & Soria-Fregozo, C. (2025) · Acta Pharmaceutica · doi:10.2478/acph-2025-0029 · Cited by 1
“%) do not respond to treatment (6), and there is a long latency period (4–6 weeks) before therapeutic effects are observed (7).”
Zhang, Y., Ju, M., Chen, S., Yang, W., Cai, Y., Yu, X., Chen, G., Shen, Z., Bai, Y., Ren, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65112-4 · Cited by 2
“2A and Supplementary Data 5).”
InfluentialCuomo, A., McIntyre, R. S., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., & Fagiolini, A. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261437597 · Cited by 1
Maruthy, G. B., Himes, L. M., Hubbard, N. A., Spence, J. S., & Rypma, B. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122331 · Cited by 1
Refractory Depression and the Right to Terminate Active Treatment
Sommer, B. R., & Raj, K. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6_4 · Cited by 1
Xie, H., Tang, Y., Cheng, F., & Chu, J. (2021) · Medicine · doi:10.1097/md.0000000000025241 · Cited by 1
Rascón-Martínez, D. M., Fresán, A., Duque-Alarcón, X., Carmona-Alvarado, A., Castellanos-Olivares, A., & Pérez‐Zepeda, M. U. (2022) · Revista Mexicana de Anestesiología · doi:10.35366/106341 · Cited by 2
Are modern neuromodulation therapies too precise?
McDonald, W. M. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.08.001 · Cited by 2
Neuromodulation Intervention in Resistant Depression
Prasetya, E. C., & Basoeki, L. (2020) · Jurnal Psikiatri Surabaya · doi:10.20473/jps.v8i2.17136 · Cited by 3
Brain Imaging and the Mechanisms of Antidepressant Action
Godlewska, B. R., Selvaraj, S., & Cowen, P. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.020 · Cited by 1
Effects of Lithium on Brain Structure in Bipolar Disorder
Kaur, J., Kafantaris, V., & Szeszko, P. R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.018 · Cited by 1
Functional Connectome in Bipolar Disorder
Cha, J., & Anand, A. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.008 · Cited by 1
de la Fuente‐Sandoval, C., Bonetto, G. G., Lacerda, A. L. T., López‐Jaramillo, C., Uribe, E. S., Tung, C. T., Cabrera, P., KANEVSKY, G. A., & Soares, B. A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.598 · Cited by 1
Sacher, M. (1987) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Yun, D., Feng, R., Zhang, W., Fang, J., Ma, K., Wang, E., & Hu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1244643/v1 · Cited by 2
Lawford‐Smith, H. (2015)
Cortical Stimulation for Depression
Gilligan, J. T., Rasouli, J. J., & Kopell, B. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00092-9 · Cited by 1
Pedersen, E. R., Kandrack, R., Danz, M., Motala, A., Booth, M. J., Larkin, J., & Hempel, S. (2018) · Rand health quarterly · doi:10.7249/rhq-09-01-06
Paradigm Shift in Study of Treatment-Resistant Psychiatric Disorder
Jeon, S. W., Amidfar, M., & Kim, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_2
Su, K., Tang, C., Chang, H.-C., Chiu, W., Lü, N., & Huang, K.-C. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000262 · Cited by 1
“There is growing evidence that depression exacts significant economic toll on individuals, family members, employers, and healthcare payers, costing an estimated $29 billion to $48 billion per year in the USA (Mrazek et al., 2014).”
BackgroundLin, A. (2019) · CORE Scholar (Wright State University)
Imaging Genetic and Epigenetic Markers in Mood Disorders
Poletti, S., Mazza, E. A., Vai, B., & Benedetti, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.012
Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders
Kumar, P., Jiang, Y., & Whitton, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.006
Resting-State Functional Connectivity in Unipolar Depression
Chen, Z., & Gong, Q. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.007
Shah, D. (2019) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3855
Brain Imaging Methods in Mood Disorders
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.002
Kious, B. M., & Renshaw, P. F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.009
Neuroimaging Brain Inflammation in Mood Disorders
Meyer, J. H. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.011
Functional Near-Infrared Spectroscopy Studies in Mood Disorders
Matsuo, K., & Matsubara, T. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.014
Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus
Arnone, D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.003
Neuroimaging Biomarkers in Pediatric Mood Disorders
West, M. P., Tang, W. J., & Singh, M. K. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.005
fMRI Neurofeedback as Treatment for Depression
Skottnik, L., & Linden, D. E. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.013
Neuroanatomical Findings in Bipolar Disorder
Tronchin, G., & McDonald, C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.004
Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders
Scotti-Muzzi, E., Otaduy, M. C. G., Soeiro‐de‐Souza, M. G., & Machado‐Vieira, R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.010
Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder
Jauhar, S. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.019
Magnetoencephalography Studies in Mood Disorders
Nugent, A. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.016
Cautious optimism and a call for additional studies
Li, M. G., & Garcia-Pittman, E. C. (2021) · International Psychogeriatrics · doi:10.1017/s1041610220001490
“While antidepressants are superior to placebo, initial treatment leads to remission in less than 50% of patients, with roughly one-third having no response to pharmacotherapy (Mrazek et al., 2014).”
BackgroundEffects of Unpredictable Chronic Mild Stress on Adolescent Rats
Kirschmann, E. K. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
Ketamine Anesthesia in Electroconvulsive Therapy
Satomoto, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101365
Houix, M., Collignon, M., & Armand-Branger, S. (2021) · Le Pharmacien Clinicien · doi:10.1016/j.phclin.2021.07.001
Peripheral biomarkers in Repeated Ketamine Infusions Trial
Geel, A. V. (2021) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2021-14775
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.022
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.001
Gorgulho, A. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-08042022-123137
Geraets, A. F. J. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210702ag
Vandeloo, K. L., Burhunduli, P., Sylvain Bouix, A., Owsia, K., Cho, K. I. K., Zhuo, F., Geel, A. V., Pasternak, O., Blier, P., & Phillips, J. L. (2022) · Research Square · doi:10.21203/rs.3.rs-1712962/v1
Zhou, H., Zhu, J., Jia, J., Xiang, W., Peng, H., Zhang, Y., Liu, B., Mu, Y., & Lu, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4138335
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-makingPreprint
Oemisch, M., & Seo, H. (2023) · bioRxiv · doi:10.1101/2022.07.25.501468 · Cited by 2
“The discovery of ketamine, a non-competitive N -methyl- D -aspartate (NMDA) receptor antagonist as a rapid-acting antidepressant, inspired extensive research to understand the mechanisms of ketamine’s action as well as a new perspective on the neurobiology of depression that depression might…”
Backgroundvon Knebel, K. A. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9504
Ma, Z., Yu, Y., Gao, M., Chen, P., Hong, H., Yu, D., Liang, Z., Ye, Q., Wang, Y., Huang, G., et al. (2022) · doi:10.22541/au.167061219.95188925/v1
Frodl, T., & Möller, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_1
Saya, S., Chondros, P., Abela, A., Mihalopolous, C., Chatterton, M. L., Gunn, J. M., Chen, T. F., Polasek, T. M., Dettmann, E., Brooks, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2840416/v1
Cigognini, M. A. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-10052023-120550
Caldieraro, M. A., Teng, C. T., Lacerda, A. L. T., Quarantini, L. C., Grabowsiky, H., KANEVSKY, G. A., & Perocco, S. (2023) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v15.n1.p39-51
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making
Oemisch, M., & Seo, H. (2024) · eLife · doi:10.7554/elife.87529 · Cited by 2
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.